CSIMarket Company Name, Ticker, Customers, else..


X4 Pharmaceuticals Inc  (NASDAQ: XFOR)
Other Ticker:  
 


 

X4 Pharmaceuticals Inc

XFOR's Financial Statements and Analysis



X4 Pharmaceuticals Inc reported in the first quarter of 2025 net earnings per share of $1.20 an improvement compare to net loss per share of $-7.80 recorded a year ago and an improvement compare to net loss per share of $-5.79 realized in previous quarter.


first quarter of 2025
Earnings Per Share Revenues
$ 1.2 $  29 Mill
$+9.00     $+29M    



X4 Pharmaceuticals Inc's Revenue rose by 0 % in first quarter of 2025 (Mar 31 2025) year on year, to $29 million and advanced by 1908.86 % sequentially.


X4 Pharmaceuticals Inc is

More on XFOR's Income Statement



X4 Pharmaceuticals Inc 's net income of $0.282 million in the first quarter of 2025 increased from net loss of $-51.766 million I. Quarter a year ago.

Sequentially Company turn into Profitability from net loss of $-39.821 million recorded in previous quarter.

More on XFOR's Growth

X4 Pharmaceuticals Inc Inventories
In Mar 31 2025 company's net cash and cash equivalents decreased by $-15 million


X4 Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period X4 Pharmaceuticals Inc payed $ -478.98 cash per share, on a free-cash flow basis .

Book value grew by 2,872.45 % sequentially to $100.21 per share, 2847.21% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value fell to $ -18.43 per share from $ -0.79.

Company repurchased 6.34 million shares or 96.52 % in Mar 31 2025.
Interest Coverage Ratio was 2.35.

• More on XFOR's Dividends

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 0
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 31
 Net Income (TTM) (Millions $) 15
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) -7
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 43




X4 Pharmaceuticals Inc does not pay out common stock dividend.

In trailing twelve-month period X4 Pharmaceuticals Inc had negative $ -478.98 cash flow per share, on a free-cash flow basis .

Book value grew by 2,872.45 % sequentially to $100.21 per share, 2847.21% of net income per share in trailing twelve-month period were contributed to shareholder value.
Tangible Book value fell to $ -18.43 per share from $ -0.79.

Company repurchased 6.34 million shares or 96.52 % in Mar 31 2025.
Interest Coverage Ratio was 2.35.

• More on XFOR's Balance Sheets

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 0
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 31
 Net Income (TTM) (Millions $) 15
 Cash Flow (TTM) (Millions $) -20
 Capital Exp. (TTM) (Millions $) -7
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 43
   


  News about X4 Pharmaceuticals Inc Earnings

X4 Pharmaceuticals Inc Reveals Jaw-Dropping $-27.214 Million Operating Shortfall in Latest Report

As the July to September 30 2023 reporting season continues, the stock market has been buzzing with updates from various companies. Among ...

XFOR's Financial Strain Continues to Grow as Operating Shortfall Soars to $-25.805 Million in Q2 2023


Introduction
As we delve into the financial performance of X4 Pharmaceuticals Inc during the April to June 30, 2023 reporting season, shareholders are presented with some interesting insights. The company's operating shortfall witnessed a significant increase compared to the previous year, leading to a substantial net deficit. Let's examine these figures in detail and contextualize the current situation at the organization.
Operating Shortfall and Financial Performance
During the second quarter of 2023, X4 Pharmaceuticals Inc faced an operating shortfall of $-25.805 million. This figure, which represents the company's expenses exceeding its revenue, raises concerns among stockholders. Compar...

X4 Pharmaceuticals Inc Sees Rising Working Costs, Despite Positive Momentum in ROI Rankings

X4 Pharmaceuticals Inc, a growing player in the biotechnology and pharmaceuticals sector, recently released its financial results for the 12 months ending in the third quarter of 2022. The company recorded a cumulative net loss of $-96 million, resulting in a negative return on investment (ROI) of -100.77%. Compared to other companies in the healthcare sector, X4 Pharmaceuticals Inc ranks lower with only 132 companies showing a higher ROI.
However, the overall ranking for ROI has progressed throughout the year, with the company's current ranking at 1101 in the first quarter of 2023, compared to its ranking in the fourth quarter...


Date modified: 2025-05-23T09:22:02+00:00





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com